US FDA rejects Pfizer rare neurodegenerative disease drug
This article was originally published in Scrip
Executive Summary
Pfizer revealed on 18 June after the markets closed that it received a complete response letter (CRL) from the US FDA for the firm's new drug application (NDA) for Vyndaqel (tafamidis meglumine), which the company is seeking to market as a therapy for transthyretin familial amyloid polyneuropathy (TTR-FAP), a rare, genetic progressive neurodegenerative disease, in which there is a buildup of amyloid, primarily in peripheral nerves, but also in the organs.
You may also be interested in...
Alnylam Plays Up Patisiran As Polyneuropathy Drug Nears Filings
Open-label extension Phase II data with RNAi candidate shows patients with transthyretin-mediated amyloidosis polyneuropathy may be regaining sensation and possibly even regenerating nerves.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.